A M Kleschevnikov

Summary

Publications

  1. pmc Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists
    Alexander M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    J Neurosci 32:9217-27. 2012
  2. pmc Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome
    Alexander M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Neurobiol Dis 45:683-91. 2012
  3. doi request reprint Discoveries in Down syndrome: moving basic science to clinical care
    A M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
    Prog Brain Res 197:199-221. 2012

Detail Information

Publications3

  1. pmc Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists
    Alexander M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    J Neurosci 32:9217-27. 2012
    ..The ability to rescue cognitive performance through treatment with selective GABA(B) receptor antagonists motivates studies to further explore the therapeutic potential of these compounds in people with DS...
  2. pmc Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome
    Alexander M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Neurobiol Dis 45:683-91. 2012
    ..Thus, both GABAA and GABAB receptor-mediated synaptic efficiency is increased in the Ts65Dn DG, thus likely contributing to deficient synaptic plasticity and poor learning in DS...
  3. doi request reprint Discoveries in Down syndrome: moving basic science to clinical care
    A M Kleschevnikov
    Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
    Prog Brain Res 197:199-221. 2012
    ..It is hoped that the identification of an increasing number of potential targets for pharmacotherapy of cognitive deficits in DS will add to the momentum for creating and completing clinical trials...